Club Drugs and Novel Psychoactive Substances: The Clinician's Handbook

ISBN-13: 9781911623090 / Angielski / Miękka / 2020 / 150 str.

Owen Bowden-Jones;Dima Abdulrahim

Opis

Emerging illicit drugs pose a significant clinical challenge. This handbook offers an engaging, concise guide to managing these challenges.

Recenzje

'A very nice reading; very easy to follow and with a clear focus on the clinical issues, e.g. what the practicing clinician … need to know to interact with the client; to make a diagnosis; and identify a proper treatment and management approach. Although the language and the tones here used are straightforward and direct, the content of the document is precise, really updated, and definitely non-judgmental. I particularly enjoyed reading the clinical vignettes; they illustrate a range of complex issues in a way which is simple enough for even the non experienced clinician/non experienced trainee to be able to understand. There are a few sections, e.g. the one on psychedelic phenethylamines and GHB, which are of particular value. The focus on GHB withdrawal is important and detailed.' Fabrizio Schifano, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire

Spis treści

Part I: 1. Introduction 2. What are NPS and Club Drugs and why are they important; 3. A brief history of NPS production and distribution; 4. Drugs classification framework for Club Drugs and NPS; 5. Clinical challenge of Club Drugs and NPS; Part II. Stimulant Drugs; 6. Stimulant drugs: introduction; 7. Stimulant drugs: cocaine; 8. Stimulant drugs: amphetamine-type; 9. Stimulant drugs: methamphetamine; 10. Stimulant drugs: MDMA; 11. Stimulant drugs: synthetic cathinones; Part III. Depressant Drugs; 12. Depressant drugs: introduction; 13. Depressant drugs: GHB/GBL; 14. Depressant drugs: Fentanyl, Fentanyl analogues and other opioid NPS; 15. Depressant drugs: Benzodiazepine NPS; 16. Depressant drugs: Ketamine and its anaologues; Part IV. Synthetic Cannabinoid Receptor Agonsits; 17. Synthetic cannabinoid receptor agonists (SCRAs); Part V. Hallucinogens; 18. Hallucinogens; Part VI. Concluding Remarks and References; 19. Concluding Remarks; 20. References.